A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer Meeting Abstract

International Collaboration

cited authors

  • Elit, L., Konner, J. A., Armstrong, D. K., Buck, M., Dean, A., Finkler, N. J., Hulstine, A., Schweizer, C., Phillips, M., Weil, S.

Publication Date

  • May 20, 2010

webpage

published in

category

volume

  • 28

issue

  • 15

WoS Citations

  • 2

WoS References

  • 0